Recombinant Human Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MAN1A1)

What is MAN1A1 and what is its primary function?

MAN1A1 (Mannosidase alpha class 1A member 1) is a Golgi-resident alpha-1,2-mannosidase involved in the maturation of asparagine-linked (Asn-linked) oligosaccharides. Its primary function is to progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2) during N-glycan processing . This trimming process is a critical step in the maturation of complex N-glycans, which ultimately affects the function of many membrane and secreted glycoproteins. MAN1A1 is also known by several alternative names including Man(9)-alpha-mannosidase and Man9-mannosidase . The enzyme plays a key role in determining the structure and composition of N-glycans on glycoproteins, which influences protein folding, stability, and biological activities.

How does MAN1A1 activity influence oligosaccharide isomer profiles?

The trimming process can generate multiple isomers depending on which branch is modified:

• Three Man8 isomers (Man8A, Man8B, and Man8C) can be generated from Man9

• Four Man7 isomers can be produced during further processing

• Three Man6 isomers can be formed as the trimming continues toward the Man5 processing intermediate

These isomers appear as sub-peaks on HPLC profiles, and changes in these sub-peak patterns indicate that factors like mitotic phosphorylation can affect MAN1A1 activity differently on different branches of the oligosaccharide structure .

How is MAN1A1 activity regulated during the cell cycle?

MAN1A1 activity is regulated during the cell cycle through phosphorylation. Alignment of MAN1A1 amino acid sequences shows that serine 12 (S12) is highly conserved across mammalian species where mitotic Golgi fragmentation has been documented . Experimental evidence confirms that MAN1A1 is phosphorylated in mitotic cells but not in interphase cells, as demonstrated by immunoprecipitation of MAN1A1 from mitotic and interphase cells followed by western blot analysis using a phospho-serine (p-Ser) antibody .

Similarly, threonine residues T2, T3, and serine S10 on the related enzyme MAN1A2 are also conserved among species, and mitotic phosphorylation of MAN1A2 has been confirmed using a phospho-threonine (p-Thr) antibody . This mitotic phosphorylation affects the enzymatic activity of these mannosidases, leading to altered glycan processing during cell division. The phosphorylation appears to be a regulatory mechanism that coordinates glycan processing with cell cycle progression.

What are the opposing roles of MAN1A1 in breast cancer versus ovarian cancer?

One of the most intriguing aspects of MAN1A1 biology is its contrasting prognostic implications in different cancer types:

In breast cancer:

In ovarian cancer:

• High MAN1A1 protein levels correlate significantly with advanced stage and the presence of distant metastasis

• Optimal debulking results with no macroscopically visible residual tumor are achieved significantly less frequently in cases with high MAN1A1 expression

• High expression of combined MAN1A1 bands (72 + 60 kDa) correlates with significantly shorter recurrence-free survival

• MAN1A1 demonstrates an unfavorable prognostic role in ovarian cancer

These opposing roles suggest that the effects of altered N-glycosylation on cancer progression are highly context-dependent and may influence different cellular processes in breast versus ovarian cancer cells.

How does MAN1A1 expression affect cellular adhesion properties?

MAN1A1 expression levels significantly impact cellular adhesion properties, which may explain its role in cancer progression:

In breast cancer:

• Low MAN1A1 expression in tumor cells results in significantly increased adhesion to endothelial cells in vitro

• Reduced MAN1A1 expression or mannosidase inhibition leads to a significantly increased adhesion of breast cancer cells to endothelial cells

• This suggests that low MAN1A1 may promote hematogenic metastasis through enhanced cell-cell adhesion

In ovarian cancer:

• The unfavorable prognostic role of MAN1A1 is likely caused by an altered ability of spheroid formation

• Spheroid formation is a critical step in ovarian cancer metastasis within the peritoneal cavity

The differential effects on adhesion may be related to the distinct metastatic patterns of these cancers:

• Breast cancer primarily spreads through lymphatic and hematogenic routes

• Ovarian cancer mainly progresses through intraperitoneal spread

These findings suggest that MAN1A1-mediated glycosylation affects specific adhesion molecules differently depending on the cellular context.

What experimental methods are used to detect and analyze MAN1A1 in research?

Several experimental approaches are used to study MAN1A1 in research settings:

Protein Expression Analysis:

• Western blot analysis using rabbit anti-α-1,2-mannosidase IA antibody (e.g., Abcam ab140613, diluted 1:1000)

• Typical observed band size: 73 kDa, with additional bands sometimes observed at 60 kDa

• Expression quantification via densitometry

Activity Assays:

• HPLC profiles to detect oligosaccharide isomers (Man9, Man8, Man7, Man6, and Man5)

• Time course studies on digestion of Man9 substrate with analysis at multiple time points

• Modeling of isomer profiles based on known specificities of mannosidases

Functional Studies:

• Mannosidase inhibition using kifunensine

• MAN1A1 silencing or knockout in cell lines

• Adhesion assays between cancer cells and endothelial cells

• Lectin blots using biotinylated ConA (concanavalin A) or PHA-E to analyze glycosylation patterns

Phosphorylation Detection:

• Immunoprecipitation followed by western blot using phospho-serine or phospho-threonine antibodies

• Nocodazole synchronization to enrich mitotic cells

These methods collectively provide comprehensive insights into MAN1A1 expression, regulation, activity, and functional consequences in different biological contexts.

How does MAN1A1 influence the prognostic relevance of adhesion molecules?

The glycosylation status mediated by MAN1A1 significantly impacts the prognostic relevance of specific adhesion molecules:

At the mRNA level, membrane proteins ALCAM (Activated leukocyte cell adhesion molecule/CD166) and CD24 were found to be significantly prognostic only in breast tumors with high MAN1A1 expression . This suggests that proper glycosylation by MAN1A1 is required for these adhesion molecules to function in their normal capacity and to serve as reliable prognostic markers.

In ovarian cancer studies, researchers examined the expression of several adhesion molecules including ALCAM/CD166, ICAM1 (Intercellular adhesion molecule 1), and Integrin β4 in relation to MAN1A1 expression . The complex interplay between MAN1A1-mediated glycosylation and these adhesion molecules appears to affect:

• The functional activity of these adhesion proteins

• Their ability to serve as prognostic indicators

• Their contribution to cancer progression and metastasis

This demonstrates that glycosylation is not merely a post-translational modification but a critical determinant of protein function that can modulate the clinical significance of important biomarkers.

What are the experimental approaches to manipulate MAN1A1 activity in vitro?

Researchers employ several strategies to manipulate MAN1A1 activity in experimental settings:

Pharmacological Inhibition:

• Kifunensine treatment (typically at 10 μM) is widely used to inhibit class I α-mannosidases including MAN1A1

• This inhibition prevents the trimming of high-mannose N-glycans and blocks the formation of complex N-glycans

• The effects are assessed through functional assays and by analyzing glycan profiles using lectin blots with ConA or PHA-E

Genetic Manipulation:

• MAN1A1 silencing using siRNA or shRNA approaches

• MAN1A1 knockout using CRISPR-Cas9 technology

• These genetic approaches allow for specific targeting of MAN1A1 without affecting other mannosidases

Expression Systems:

• Recombinant expression of wild-type or mutant MAN1A1 (e.g., phosphorylation site mutants)

• These systems can be used to study the structure-function relationships and regulatory mechanisms

Functional Readouts:

• Cell adhesion assays measuring attachment to endothelial cells or extracellular matrix components

• Spheroid formation assays, particularly relevant for ovarian cancer research

• Migration and invasion assays to assess metastatic potential

• Glycan profiling using mass spectrometry or HPLC

These approaches provide complementary information about the role of MAN1A1 in cellular physiology and pathology, allowing researchers to elucidate the mechanistic links between altered glycosylation and disease progression.

How can MAN1A1 phosphorylation sites be identified and their functional significance determined?

The identification and functional characterization of MAN1A1 phosphorylation sites involve several methodological approaches:

Identification of Phosphorylation Sites:

• Sequence alignment across species to identify conserved potential phosphorylation sites (e.g., S12 in MAN1A1)

• Mass spectrometry-based phosphoproteomic analysis of purified MAN1A1 from mitotic versus interphase cells

• Immunoprecipitation of MAN1A1 followed by western blotting with phospho-specific antibodies (p-Ser, p-Thr)

Functional Characterization:

• Site-directed mutagenesis to create phospho-mimetic (S/T to D/E) or phospho-deficient (S/T to A) mutants

• Expression of wild-type versus mutant MAN1A1 in appropriate cellular models

• Enzymatic activity assays comparing wild-type and mutant forms using HPLC analysis of oligosaccharide isomer profiles

• Analysis of Golgi morphology and function in cells expressing different MAN1A1 variants

• Time course studies to determine the kinetics of MAN1A1 phosphorylation during cell cycle progression

Regulatory Mechanisms:

• Identification of kinases responsible for MAN1A1 phosphorylation using kinase inhibitors or genetic approaches

• Investigation of phosphatases involved in MAN1A1 dephosphorylation

• Analysis of the coordination between MAN1A1 phosphorylation and other mitotic events

Understanding the regulation of MAN1A1 through phosphorylation provides insights into how glycan processing is integrated with cell cycle progression and may reveal novel therapeutic targets for diseases associated with aberrant glycosylation.

How can MAN1A1 expression be reliably assessed in patient samples?

Reliable assessment of MAN1A1 expression in patient samples is critical for prognostic studies and potential therapeutic applications:

Protein Level Detection:

• Western blot analysis using validated antibodies (e.g., rabbit anti-α-1,2-mannosidase IA antibody, Abcam ab140613)

• Immunohistochemistry on tissue sections with appropriate positive and negative controls

• Typically, MAN1A1 appears as a 73 kDa band, with an additional 60 kDa band sometimes observed

• For prognostic studies, patients can be stratified into groups based on expression levels (e.g., below or above median expression)

mRNA Level Assessment:

• RT-qPCR for targeted analysis of MAN1A1 transcript levels

• Microarray data analysis from archived datasets

• RNA-seq for comprehensive transcriptomic profiling

Experimental Considerations:

• Use of appropriate loading controls (β-Actin, GAPDH) for normalization

• Inclusion of positive control cell lines (e.g., MDA-MB231 for breast cancer studies)

• Quantification via densitometry for western blot analysis

• Statistical analysis using appropriate methods (e.g., Chi-square tests for correlations with clinicopathological parameters, Kaplan-Meier and Cox regression for survival analysis)

These methodological approaches enable reliable assessment of MAN1A1 expression in patient samples, which is essential for understanding its role as a prognostic biomarker in different cancer types.

What is the potential of MAN1A1 as a therapeutic target in cancer?

Based on the contrasting roles of MAN1A1 in different cancer types, its potential as a therapeutic target requires careful consideration:

In Breast Cancer:

• Since low MAN1A1 correlates with poor prognosis , strategies to increase MAN1A1 expression or activity might be beneficial

• Targeting upstream regulators that suppress MAN1A1 expression

• Developing compounds that enhance MAN1A1 activity

• Targeting the altered glycosylation patterns resulting from low MAN1A1 expression

In Ovarian Cancer:

• High MAN1A1 expression correlates with unfavorable prognosis , suggesting inhibition might be beneficial

• Selective inhibitors of MAN1A1 might reduce spheroid formation ability

• Targeting downstream effects on adhesion molecules

• Combination approaches with existing chemotherapy regimens

Challenges and Considerations:

• Tissue-specific effects require careful targeting to avoid unintended consequences

• The fundamental role of MAN1A1 in normal glycan processing may limit the therapeutic window

• Patient stratification based on MAN1A1 expression would be essential for any targeted approach

• Potential for compensatory mechanisms through other mannosidases

Research approaches to evaluate MAN1A1 as a therapeutic target include:

• In vitro studies with specific inhibitors or enhancers of MAN1A1 activity

• Animal models with tissue-specific modulation of MAN1A1 expression

• Combination studies with established therapeutic agents

• Analysis of glycan profiles as pharmacodynamic biomarkers

The contrasting roles of MAN1A1 in different cancers highlight the complexity of targeting glycosylation enzymes and emphasize the need for context-specific approaches.

How do changes in MAN1A1 expression correlate with specific clinicopathological parameters?

MAN1A1 expression correlates with different clinicopathological parameters depending on the cancer type:

In Breast Cancer:

• Low MAN1A1 expression correlates significantly with:

  • Positive lymph node status (increased nodal involvement)

  • Higher histological grade (G3 vs. G1/2)

  • Increased incidence of brain metastasis

  • Shorter disease-free intervals

• These correlations support the tumor-suppressor function of MAN1A1 in breast cancer

In Ovarian Cancer:

• High MAN1A1 protein levels (analyzing both the 72 kDa and combined 72+60 kDa bands) correlate significantly with:

  • Advanced FIGO stage (III/IV vs. I/II)

  • Presence of distant metastasis

  • Positive lymph node status (for combined bands)

  • Less frequent achievement of optimal debulking (no visible residual tumor)

  • Shorter recurrence-free survival

• These associations suggest a tumor-promoting role of MAN1A1 in ovarian cancer

Statistical Methods Used:

• Chi-square tests to examine correlations between MAN1A1 expression and clinicopathological factors

• Kaplan-Meier analysis and Log-Rank Tests for survival curves

• Hazard ratios calculated by uni- or multivariate Cox regression analysis

These opposing correlations emphasize the context-dependent role of MAN1A1 in cancer biology and highlight the importance of cancer type-specific approaches when considering MAN1A1 as a biomarker or therapeutic target.

What are the key considerations for analyzing MAN1A1 enzymatic activity?

Analyzing MAN1A1 enzymatic activity requires specific methodological approaches:

Substrate Preparation:

• Man9GlcNAc2 is used as the primary substrate for assessing MAN1A1 activity

• Substrates can be labeled with fluorescent tags for detection

• Purified substrates must be of high quality to ensure reliable results

Activity Assay Methods:

• HPLC analysis to separate and quantify different oligosaccharide products (Man8, Man7, Man6, Man5)

• Specific detection of oligosaccharide isomers (Man8A, Man8B, Man8C, etc.) as sub-peaks on HPLC profiles

• Time course studies (e.g., 30 and 60 min timepoints) to determine reaction kinetics

• Use of purified enzymes or membrane preparations (RLG and MGF membrane preparations)

Data Analysis:

Controls and Validation:

• Inclusion of specific inhibitors (e.g., kifunensine) as negative controls

• Use of purified recombinant enzymes as positive controls

• Validation of activity findings with genetic approaches (siRNA, CRISPR)

These methodological considerations ensure accurate assessment of MAN1A1 enzymatic activity and its contribution to N-glycan processing in different cellular contexts.

How can researchers distinguish between the effects of MAN1A1 and other mannosidases?

Distinguishing the specific effects of MAN1A1 from those of other mannosidases requires careful experimental design:

Biochemical Approaches:

• Substrate specificity analysis: MAN1A1, MAN1A2, and MAN1B1 have different preferences for specific mannose residues on the N-glycan structure

• Isomer profile analysis: Each mannosidase produces a characteristic pattern of isomers (Man8A, Man8B, Man8C, etc.)

• Kinetic analyses to determine the rate constants for different mannosidases

Genetic Approaches:

• Specific knockdown or knockout of MAN1A1 using siRNA, shRNA, or CRISPR-Cas9

• Rescue experiments with wild-type or mutant MAN1A1 expression

• Comparison of phenotypes between MAN1A1, MAN1A2, and MAN1B1 knockdowns

Pharmacological Approaches:

• While kifunensine inhibits all class I α-mannosidases, more selective inhibitors may be available

• Dose-response studies to identify concentration ranges that might preferentially affect different mannosidases

Analytical Methods:

• Mass spectrometry to determine detailed glycan structures

• Modeling approaches that incorporate the known specificities of MAN1B1, MAN1A1, and MAN1A2 to predict their relative contributions to glycan processing

• Analysis of the ratios between different isomers to infer the activity of specific mannosidases

Expression Analysis:

• Quantitative proteomics to determine the relative abundance of different mannosidases (e.g., the 27:14:12 ratio for MAN1A1:MAN1A2:MAN1B1 in Golgi membranes)

• Assessment of subcellular localization to distinguish ER-resident (e.g., MAN1B1) from Golgi-resident mannosidases

These approaches collectively enable researchers to distinguish the specific contributions of MAN1A1 from those of other mannosidases in glycan processing and cellular physiology.

What are the common technical challenges in MAN1A1 research and how can they be addressed?

MAN1A1 research presents several technical challenges that researchers should be aware of:

Antibody Specificity:

• Challenge: Ensuring antibody specificity for MAN1A1 versus other mannosidases

• Solution: Validate antibodies using knockout/knockdown controls and peptide competition assays

• Example: The rabbit anti-α-1,2-mannosidase IA antibody (Abcam ab140613) has been validated for western blot applications

Multiple Protein Bands:

• Challenge: MAN1A1 may appear as multiple bands (73 kDa and 60 kDa) in western blots

• Solution: Consider both bands separately and in combination for correlation analyses

• Finding: The combined expression of both bands showed significant associations with advanced stage, positive lymph node status, and distant metastasis in ovarian cancer

Complex Glycan Analysis:

• Challenge: Distinguishing between multiple isomers of oligosaccharides

• Solution: Use high-resolution HPLC methods and mass spectrometry

• Approach: Analyzing sub-peaks representing different isomers (Man8A, Man8B, Man8C) on HPLC profiles

Functional Redundancy:

• Challenge: Other mannosidases may compensate for MAN1A1 loss in knockout/knockdown studies

• Solution: Use combinatorial approaches targeting multiple mannosidases

• Consideration: Analyze the expression and activity of MAN1A2 and MAN1B1 in parallel with MAN1A1

Tissue-Specific Effects:

• Challenge: MAN1A1 has opposing roles in different cancer types

• Solution: Always consider the specific cellular context in experimental design and data interpretation

• Example: Compare breast cancer models (where MAN1A1 appears tumor-suppressive) with ovarian cancer models (where MAN1A1 appears tumor-promoting)

Activity versus Expression:

• Challenge: Protein expression levels may not directly correlate with enzymatic activity

• Solution: Complement expression studies with functional activity assays

• Example: Mitotic phosphorylation affects MAN1A1 activity without changing protein levels